TY - JOUR
T1 - Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer
AU - Jones, L
AU - Hornsby, Whitney
AU - Goetzinger, Amy
AU - Forbes, Lindsay
AU - Sherrard, Emily
AU - Quist, Morten
AU - Lane, Amy
AU - West, Miranda
AU - Eves, Neil
AU - Gradison, Margaret
AU - Coan, April
AU - Herndon, James
AU - Abernethy, Amy
PY - 2012/5
Y1 - 2012/5
N2 -
Background: To investigate the prognostic importance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer (NSCLC). Patients and methods: Using a prospective design, 118 consecutive participants with histologically confirmed metastatic (inoperable) NSCLC and Eastern Cooperative Oncology group (ECOG) 0-3 completed a six-minute walk test to assess functional capacity and questionnaire that assessed self-reported exercise behavior. Cox proportional models were used to estimate the risk of all-cause mortality according to six-minute walk distance (6MWD) (<358.5m, 358.5-450m, ≥450m) and exercise behavior (MET-hrswk
-1
) categories with adjustment for important covariates. Results: Median follow-up was 26.6 months; 77 deaths were reported during this period. Functional capacity was an independent predictor of survival (P
trend
=0.003) and added incremental prognostic value beyond that provided by PS plus other traditional markers of prognosis (P
trend
=0.025). Compared with patients achieving a 6MWD <358.5m, the adjusted hazard ratio (HR) for all-cause mortality was 0.61 (95% CI, 0.34-1.07) for a 6MWD of 358.5-450m, and 0.48 (95% CI, 0.24-0.93) for a 6MWD >450m. In unadjusted analysis, there was a borderline significant effect of exercise behavior on survival (p=0.052). Median survival was 12.89 months (95% CI, 9.11-21.05 months) for those reporting <9MET-hrswk
-1
compared with 25.63 months (95% CI, 11.28 to ∞ months) for those reporting ≥9MET-hrswk
-1
. Conclusions: Functional capacity is a strong independent predictor of survival in advanced NSCLC that adds to the prediction of survival beyond traditional risk factors. This parameter may improve risk stratification and prognostication in NSCLC.
AB -
Background: To investigate the prognostic importance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer (NSCLC). Patients and methods: Using a prospective design, 118 consecutive participants with histologically confirmed metastatic (inoperable) NSCLC and Eastern Cooperative Oncology group (ECOG) 0-3 completed a six-minute walk test to assess functional capacity and questionnaire that assessed self-reported exercise behavior. Cox proportional models were used to estimate the risk of all-cause mortality according to six-minute walk distance (6MWD) (<358.5m, 358.5-450m, ≥450m) and exercise behavior (MET-hrswk
-1
) categories with adjustment for important covariates. Results: Median follow-up was 26.6 months; 77 deaths were reported during this period. Functional capacity was an independent predictor of survival (P
trend
=0.003) and added incremental prognostic value beyond that provided by PS plus other traditional markers of prognosis (P
trend
=0.025). Compared with patients achieving a 6MWD <358.5m, the adjusted hazard ratio (HR) for all-cause mortality was 0.61 (95% CI, 0.34-1.07) for a 6MWD of 358.5-450m, and 0.48 (95% CI, 0.24-0.93) for a 6MWD >450m. In unadjusted analysis, there was a borderline significant effect of exercise behavior on survival (p=0.052). Median survival was 12.89 months (95% CI, 9.11-21.05 months) for those reporting <9MET-hrswk
-1
compared with 25.63 months (95% CI, 11.28 to ∞ months) for those reporting ≥9MET-hrswk
-1
. Conclusions: Functional capacity is a strong independent predictor of survival in advanced NSCLC that adds to the prediction of survival beyond traditional risk factors. This parameter may improve risk stratification and prognostication in NSCLC.
KW - Cardiorespiratory fitness
KW - Exercise
KW - Functional assessment
KW - Prognosis
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=84859423946&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2011.10.009
DO - 10.1016/j.lungcan.2011.10.009
M3 - Article
VL - 76
SP - 248
EP - 252
JO - Lung Cancer
JF - Lung Cancer
SN - 0169-5002
IS - 2
ER -